GeneDx To Present New Results At International Consortium On Newborn Sequencing For Its Genomic Newborn Screening
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new findings to be presented at the International Consortium on Newborn Sequencing
Share
Why It Matters
GeneDx will show new test results at a big science meeting. Watch if doctors start using their newborn screening more widely.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.